Sunitinib

In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]

In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]

Sunitinib as first-line systemic therapy was associated with a median PFS of 11 months, compared with 5 months for interferon alfa.

In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]

The HR for progression was 0.42 (95% CI, 0.32–0.54; P < .001).[12][Level of evidence B1]

In 750 previously untreated patients, all of whom had clear cell kidney cancer, a phase III trial compared sunitinib with interferon alfa.[12] Bevacizumab, a monoclonal antibody that binds to and neutralizes circulating VEGF protein, delayed progression of clear-cell renal cell carcinoma when compared with placebo in patients with disease refractory to biological therapy.[32] Similarly, bevacizumab plus interferon alfa as first-line therapy resulted in longer PFS but not OS compared with interferon alfa alone in two similarly designed, randomized, controlled trials.[33,34]

However, the analysis for OS showed a strong but statistically nonsignificant trend to improved survival (26.4 months vs. 21.8 months; HR, 0.82; 95% CI, 0.669–1.001; P = .051).[13][Level of evidence B1]